To address this question we have used the BALB/c-CT26 murine tumor model and we have tested whether the efficacy of a vaccine constituted by OMVs decorated with five CT26-specific neo-epitopes [12,16] could be potentiated by Bifidobacterium administration during vaccination. The gene discussed is DDX53; the disease is neoplasm.